Beigene (NASDAQ:BGNE) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Monday, January 8th.
According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. “
A number of other analysts have also commented on the stock. Cowen reissued a “buy” rating on shares of Beigene in a research report on Monday, January 8th. BidaskClub raised shares of Beigene from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Maxim Group set a $120.00 price target on shares of Beigene and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. ValuEngine downgraded shares of Beigene from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Finally, Robert W. Baird restated a “neutral” rating and issued a $83.00 price target (up from $58.00) on shares of Beigene in a research note on Tuesday, November 14th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. Beigene presently has a consensus rating of “Hold” and a consensus price target of $96.67.
Beigene (NASDAQ:BGNE) last released its quarterly earnings results on Monday, November 13th. The company reported $2.54 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $2.31. The company had revenue of $220.21 million during the quarter, compared to analyst estimates of $1.55 million. During the same quarter last year, the company earned ($1.08) EPS. equities research analysts forecast that Beigene will post -2.04 EPS for the current fiscal year.
In other news, CMO Amy C. Peterson sold 3,601 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $82.96, for a total transaction of $298,738.96. Following the completion of the sale, the chief marketing officer now owns 1,201 shares of the company’s stock, valued at approximately $99,634.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO John Oyler sold 150,957 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $80.50, for a total transaction of $12,152,038.50. Following the sale, the chief executive officer now directly owns 491,891 shares of the company’s stock, valued at approximately $39,597,225.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 483,482 shares of company stock worth $42,139,474. 19.90% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can grew its position in Beigene by 3.8% in the 4th quarter. Bank of Montreal Can now owns 16,186 shares of the company’s stock valued at $1,581,000 after purchasing an additional 600 shares during the period. Belpointe Asset Management LLC purchased a new position in Beigene during the 3rd quarter worth $1,642,000. California Public Employees Retirement System purchased a new position in Beigene during the 3rd quarter worth $4,912,000. Perceptive Advisors LLC purchased a new position in Beigene during the 3rd quarter worth $590,000. Finally, Orbimed Advisors LLC boosted its holdings in Beigene by 2.0% during the 3rd quarter. Orbimed Advisors LLC now owns 1,313,788 shares of the company’s stock worth $135,925,000 after acquiring an additional 26,200 shares during the last quarter. 55.32% of the stock is owned by institutional investors and hedge funds.
WARNING: This piece was posted by BBNS and is the property of of BBNS. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/beigene-bgne-stock-rating-lowered-by-zacks-investment-research/1822962.html.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.